I-O trials have a mixed record of hitting on OS after missing on PFS, so this trial could yet show a statsig survival benefit. On the other hand, the PFS miss is likely to reinforce the drumbeat that adding Yervoy to Opdivo doesn’t accomplish much (except in first-line melanoma).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.